Last reviewed · How we verify
Dorzolamide 2% drops
Dorzolamide 2% drops is a Carbonic anhydrase inhibitor Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved. Also known as: Pio-bag (2%), Iop-Sox (2%), Trusopt.
Dorzolamide 2% drops is an ophthalmic solution developed by the University Health Network in Toronto. It is not approved by the FDA and is primarily used off-label for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. The drug works by inhibiting carbonic anhydrase, reducing the production of aqueous humor. Despite its off-label use, it has shown efficacy in clinical settings, but its lack of FDA approval limits its broader adoption. Safety concerns include common side effects such as eye irritation, blurred vision, and taste disturbances. The drug's commercial potential is limited due to its off-label status and the availability of FDA-approved alternatives.
At a glance
| Generic name | Dorzolamide 2% drops |
|---|---|
| Also known as | Pio-bag (2%), Iop-Sox (2%), Trusopt |
| Sponsor | University Health Network, Toronto |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Augmented Macular Pigment-containing Nutraceutical and Central Visual Function (PHASE4)
- Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema (PHASE2, PHASE3)
- Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PHASE1)
- Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) (PHASE3)
- Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy (NA)
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dorzolamide 2% drops CI brief — competitive landscape report
- Dorzolamide 2% drops updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Dorzolamide 2% drops
What is Dorzolamide 2% drops?
Who makes Dorzolamide 2% drops?
Is Dorzolamide 2% drops also known as anything else?
What drug class is Dorzolamide 2% drops in?
What development phase is Dorzolamide 2% drops in?
What does Dorzolamide 2% drops target?
Related
- Drug class: All Carbonic anhydrase inhibitor drugs
- Target: All drugs targeting Carbonic anhydrase II
- Manufacturer: University Health Network, Toronto — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Also known as: Pio-bag (2%), Iop-Sox (2%), Trusopt
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing